Rocco D - Search Results

1

What pharmacotherapeutics should one use for early stage non-small cell lung cancer?

Battiloro C, Della Gravara L, Rocco D, Gridelli C. Battiloro C, et al. Among authors: rocco d. Expert Opin Pharmacother. 2018 Sep;19(13):1403-1406. doi: 10.1080/14656566.2018.1510915. Epub 2018 Aug 16. Expert Opin Pharmacother. 2018. PMID: 30113230 No abstract available.

2

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.

Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P. Botta C, et al. Among authors: rocco d. Cancer Biol Ther. 2013 Jun;14(6):469-75. doi: 10.4161/cbt.24425. Cancer Biol Ther. 2013. PMID: 23760488 Free PMC article.

3

Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples.

Pepe F, De Luca C, Smeraglio R, Pisapia P, Sgariglia R, Nacchio M, Russo M, Serra N, Rocco D, Battiloro C, Ambrosio F, Gragnano G, Vigliar E, Bellevicine C, Troncone G, Malapelle U. Pepe F, et al. Among authors: rocco d. J Clin Pathol. 2019 Jan;72(1):38-45. doi: 10.1136/jclinpath-2018-205386. Epub 2018 Oct 2. J Clin Pathol. 2019. PMID: 30279174

4

Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond.

Rocco D, Battiloro C, Gravara LD, Gridelli C. Rocco D, et al. Rev Recent Clin Trials. 2019;14(2):120-128. doi: 10.2174/1574887114666181205155211. Rev Recent Clin Trials. 2019. PMID: 30520383 Review.

5

Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.

Rocco D, Battiloro C, Della Gravara L, Gridelli C. Rocco D, et al. Drug Saf. 2019 Feb;42(2):199-209. doi: 10.1007/s40264-018-0771-y. Drug Saf. 2019. PMID: 30649741 Review.

6

First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future development.

Rocco D, Della Gravara L, Battiloro C, Gridelli C. Rocco D, et al. Expert Rev Respir Med. 2022 Mar;16(3):315-321. doi: 10.1080/17476348.2019.1600824. Epub 2019 Apr 2. Expert Rev Respir Med. 2022. PMID: 30920858

7

The role of combination chemo-immunotherapy in advanced non-small cell lung cancer.

Rocco D, Della Gravara L, Battiloro C, Gridelli C. Rocco D, et al. Expert Rev Anticancer Ther. 2019 Jul;19(7):561-568. doi: 10.1080/14737140.2019.1631800. Epub 2019 Jun 25. Expert Rev Anticancer Ther. 2019. PMID: 31188040 Review.

8

The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.

Rocco D, Gravara LD, Gridelli C. Rocco D, et al. Curr Clin Pharmacol. 2020;15(1):11-19. doi: 10.2174/1574884714666190809124555. Curr Clin Pharmacol. 2020. PMID: 31400270 Free PMC article. Review.

9

Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer.

Rocco D, Malapelle U, Del Re M, Della Gravara L, Pepe F, Danesi R, Troncone G, Gridelli C. Rocco D, et al. Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):87-96. doi: 10.1080/17425255.2020.1721460. Epub 2020 Jan 30. Expert Opin Drug Metab Toxicol. 2020. PMID: 31978315 Review.

10

Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?

Gravara LD, Battiloro C, Cantile R, Letizia A, Vitiello F, Montesarchio V, Rocco D. Gravara LD, et al. Among authors: rocco d. Lung Cancer Manag. 2020 Feb 12;9(1):LMT22. doi: 10.2217/lmt-2019-0018. Lung Cancer Manag. 2020. PMID: 32256708 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

261 results

Search Page